AGP Executive Report
Last update: 4 hours agoMedical Breakthrough: The European Commission has granted marketing authorisation under exceptional circumstances for NEZGLYAL® (leriglitazone), the first EU pharmacological treatment for childhood cerebral adrenoleukodystrophy (cALD) in boys aged 2–12 with Gd-negative brain lesions, with Germany launch expected by year-end. EU Health Tech: The EMA CHMP issued a positive opinion for perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer (MIBC), now headed to an EC decision for EU/EEA use including Liechtenstein. Onchain Finance: Ondo launched tokenised “Intelligent Portfolios” powered by BlackRock strategies, letting investors mint/redeem one onchain token for a basket with onchain-visible allocations and rebalancing. Space & Research: CSA and Starlab Space are building a pathway to move Swiss/Liechtenstein experiments from ground tests and parabolic flights to the ISS, with selected projects gaining free ISS access. Border Tech: The EU’s entry/exit system (EES) rollout is still uneven, with at least nine countries allowed to pause full implementation into 2026 while facial and fingerprint checks catch up. AI in Education: New EC reports say generative AI can help or hinder learning depending on how it’s used, and that teachers need strong training plus clear institutional rules.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
